Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

NGF-574 h introduction

948 views

Published on

An innovative haircare active ingredient based on stem cell science and technology developed by Medipost and commercialized by Celino in Korea and worldwide

Published in: Health & Medicine
  • Reasons why you should know this homemade recipe to stop your hair loss ◆◆◆ https://tinyurl.com/y49r9d8j
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

NGF-574 h introduction

  1. 1. 01 NGF-574H www.celino.co.kr www.medi-post.com
  2. 2. 01 Stem cell conditioned media • Stem cell conditioned media is a collection of signal transduction molecules (i.e. growth factors, cytokines and chemokines) secreted by stem cell during proliferation or differentiation, having a proven potency to activate aging indigenous cells including hair follicular cells • Stem cell conditioned media thus is able to reverse or at least delay skin aging process if used as an active ingredient for desired purposes Activation of indigenous cells
  3. 3. 01 NGF-574H: primed stem cell conditioned media for hair growth • Human stem cell conditioned media is allowed to be used in cosmetic products in advanced countries like US, Japan and Korea by regulatory authorities; • The composition of the conditioned media can be controlled by appropriate pretreatment of the stem cells prior to secretion of trophic factors (process called “priming”); • NGF-574H is a human cord blood derived stem cell (hUCB-MSC) conditioned media optimized to facilitate hair growth by Medipost’s proprietary priming technology.
  4. 4. 01 • The primed conditioned media candidates were tested for hair growth potency; • NGF-574H (CM-3) resulted in 51% increase compared with control in hair length in ex vivo experiment with human hair follicles. POC: ex vivo experiment with human hair follicles
  5. 5. 01 POC (2): clinical studies Phototrichogram for hair density hair density hair diameter hair growth rate • A toxicity study was completed based on the MFDS (KFDA) guideline; • A POC clinical trial was designed in total 16 weeks use once daily by topical administration; • Total 30 subjects were tested in a placebo controlled double blind trial; • Subject groups using a formulation containing 5% NGF-574H showed superiority in total hair count (hair density), hair diameter and hair growth rate compared with placebo control group (treated with vehicle formulation only).
  6. 6. • Despite shorter length of treatment period (16w vs.48 w), the efficacy of NGF-574H seems comparable or even superior to medications available in the market for alopecia. * Subject # tested Dosing period Protocol Hair density improvement (in cm^2) Hair density improvement (%) Manufacturer NGF-574H 30 16w NGF-574H 5% solution, 1x/day, topical 13.4 13.8% MEDIPOST Minoxidil (Rogain) 393 48w Minoxidil 2% solution, 2X/day , topical 12.7 8.8% Roche Minoxidil (Rogain) 393 48w Minoxidil 5% solution, 2X/day , topical 18.6 12.3% Roche Finasteride (Prosca) 693 36w Finasteride 5mg tab, 1X/day, oral 12.9 7.7% MSD Dutasteride (Avodart) 416 36w Dutasteride 0.1mg tab, 1X/day, oral 15.4 8.7% GSK POC (3): Efficacy comparison (literature survey)
  7. 7. Current Status • Awarded New Excellent Health Technology by Ministry of Health and Welfare Korea; • Bigger scale 24 week POC clinical trial (total 84 male and female subjects) for 24 weeks will be completed in Aug 2019; • Patent pending in major countries including US and Japan • Market launch is due in 3Q 2019 exclusive for clinics and hospitals.

×